Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Dec 21;17(12):e0279331. doi: 10.1371/journal.pone.0279331

Bupivacaine as a euthanasia agent for African Clawed Frogs (Xenopus laevis)

Kaela Navarro 1,*,#, Katechan Jampachaisri 2,, David Chu 1,, Cholawat Pacharinsak 1,#
Editor: Michael Klymkowsky3
PMCID: PMC9770357  PMID: 36542627

Abstract

Immersion in tricaine methanesulfonate (i.e. TMS) has been used for euthanasia of Xenopus laevis (African Clawed frogs). However, the time for preparation and potential human health hazards may pose as a barrier for large group culls. Here, we aimed to investigate whether immersion in bupivacaine is an effective means to euthanize this species. In experiment one, frogs (n = 10/group) were randomly assigned to 1-h immersion in 1 of 3 treatment groups: 1) TMS-5 (MS-222, 5g/L); 2) TMS-10 (MS-222, 10 g/L); or 3) Bupi-1.5 (0.5% Bupivacaine, 1.5 g/L). Frogs were then removed from solutions, rinsed with system water, and placed into a recovery cage. Heart rate was evaluated audibly via doppler ultrasound flow over 1 min at immediate removal (T1h), at 2 (T2h), and 3 (T3h) h in the recovery cage. In experiment two, frogs (n = 7/group) underwent 5-h & 19-h immersion in either TMS-5 or Bupi-1.5, with heart rate assessment at 5 and 19 hrs. Righting reflex and withdrawal reflex of the hindlimb were tested during the experiments. Experiment one—after the 1-h immersion, Bupi-1.5 treated animals had decreased heart rates compared to TMS-5 and TMS-10 treated animals by T2h. Neither TMS-5, TMS-10, nor Bupi-1.5 ceased heart rate after the 1-h immersion. Experiment two—after the 5-h immersion, Bupi-1.5 and TMS-5 treated animals were comparable in heart rates. 43% of TMS-5 animals and 14% of the Bupi-1.5 animals had completely ceased heart rates at T5h. At 19 h all remaining animals exhibited rigor mortis and had ceased heart rate. We recommend 19-h of immersion using either TMS-5 or Bupi-1.5 for cessation of heart rate in African Clawed frogs. These data are strong support for the use of secondary physical methods for euthanasia in African Clawed frogs when euthanasia by immersion is performed.

Introduction

Euthanasia is a necessary task in the field of laboratory animal medicine and animal research. The vast majority of animals utilized in research are mice and rats, thus much is known about welfare, physiologic processes, and techniques employed for euthanasia of these species [1]. However, non-mammalian species are also frequently involved in research and Xenopus laevis (African Clawed frogs) are one such species. African Clawed frogs are animal models used experimentally in the fields of developmental biology, endocrinology, and toxicology [2]. They are also an attractive model for their relative ease of husbandry, inducible egg production, and short generation time. These animals are commonly housed in colonies and at times culls of large groups of animals may be necessary, such as in mass disease outbreak or in the emergency of an aquatic system failure. The process of euthanasia for these frogs can be challenging to perform due to differences from rodents, such as anatomical landmarks used for certain euthanasia methods, lack of grimace scales to determine stress or pain, difference of metabolism of drugs, and the ability to hold their breath underwater.

Despite these differences, an effective and humane euthanasia is still warranted. The 2020 AVMA Euthanasia Guidelines advocate for euthanasia techniques incorporating rapid loss of consciousness, followed by cardiac or respiratory arrest, and ultimately loss of brain function, while minimizing distress prior to loss of consciousness [3]. Current recommendations of primary euthanasia techniques for amphibians include intravenous or intracoelomic injection of sodium pentobarbital or physical penetrative methods, such as decapitation followed by pithing, after being anesthetized [3, 4]. Euthanasia by sodium pentobarbital injection not only requires high dosages, and shows inconsistent time until loss of consciousness is achieved, but can be laborious to perform in a reasonable time period for larger groups of animals, such as might be warranted in a disease outbreak scenario or aquatic system failure scenario [5]. The physical penetrative methods must be performed under anesthesia, can be technically challenging, and can contribute towards compassion fatigue in animal care personnel [2, 3]. Immersion in a drug containing solution is one route which can be utilized to circumvent the challenges faced with the previously described methods [5]. As aquatic amphibians have semi-permeable skin that allows for water soluble drugs to be metabolized through absorption, immersion in a solution of a euthanasia agent provides a potential euthanasia method [68].

Tricaine methanesulfonate (MS-222, TMS) is a derivative of the local anesthetic benzocaine, and has sodium-channel blocking activity, preventing neural transmission of mechanosensory stimuli. Immersion in a solution of TMS induces general anesthesia in aquatic animals, the dose of which is dependent on species and life stage [811]. It has also been investigated and used for euthanasia purposes in fish and amphibians. Immersion in TMS at 5 g/L for at least 1 h is described within the American Veterinary Medical Association (AVMA) Euthanasia Guidelines as a method for euthanasia of African Clawed frogs [3, 5]. However, use of TMS has drawbacks: it has a pH of 3.0, which can be irritating to the animal’s skin, so it must be buffered to neutral pH before use [12]. Additionally, TMS exposure for animal care personnel has been associated with retinal toxicity and irritation to the respiratory tract if either the powder or vapor fumes of the liquid are inhaled posing a human health hazard [13, 14]. Thus, using an alternative drug mixed into water for euthanasia purposes may provide the same advantages as TMS without the labor or human health hazard challenges.

In this study we compared the effect of bupivacaine, a local anesthetic, to TMS on heart rate during the euthanasia process to assess its potential as a euthanasia agent. We chose bupivacaine because it is a non-controlled substance, does not require extensive preparation like TMS, and does not pose the same exposure toxicity as TMS to humans. In vitro experiments assessing the effect of bupivacaine on atrial fibers of frogs have shown the drug to have a negative chronotropic effect [15, 16]. We also observed this effect on heart rates of African Clawed frogs in a pilot study. Thus, we hypothesized immersing African Clawed frogs in bupivacaine at a concentration of 1.5 g/L would have an equal effect on heart rate as TMS at 5 g/L.

Materials and methods

Animals and husbandry

Adult female African clawed frogs (Xenopus laevis, n = 44; Nasco, Fort Atkinson, WI) were utilized. The animals used in this study were non-experimental retired egg layers. Animals were group housed in recirculating water tanks at a density of 1 frog per 4 liters water with a PVC pipe for enrichment and fed a commercial diet (Frog Brittle, Nasco) twice weekly at approximately one gram per frog. Daily water quality assessments were made and quality was maintained within the following parameters: water temperature between 16–21°C, pH between 6.5–8.5, conductivity between 500–3000 μS, ammonia (NH3) less than 0.05mg/L, nitrite (NO2-) < 0.1 mg/L, and nitrate (NO3-) < 50 mg/L. The frog colony was PCR negative for Batrachochytrium dendrobatitidis, Mycobacterium chelonae, M. gordonae, M. marinum, Pseudocapilaroides xenopi, and Ranavirus. All experiments were approved by Stanford University’s Administrative Panel for Laboratory Animal Care. All frogs were raised in accordance with the Guide for the Care and Use of Laboratory Animals in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International.

Study design

We consulted with a statistician (KJ) during experimental design to determine the number of animals needed to generate statistical significance. All animals were in appropriate physical condition and health as deemed by institutional veterinarians, thus none were excluded from study. For experiment 1, evaluators were blinded to all experimental groups; groups were revealed at the end of the experiment. Due to the number of groups in experiment 2, euthanasia solutions were known. All solutions had a total volume of 0.5 L/frog in a transparent plastic container. The pH of each solution was measured using a handheld pH probe (Hanna Instruments, Woonsocket, RI) and buffered to a neutral pH using sodium bicarbonate (Doctors Foster & Smith, Rhinelander, WI), as needed. The final pH of all solutions ranged from 7–7.05. Animals were immersed in solution at staggard time points to allow for adequate heart rate & reflex assessments. Tank location was not accounted for in possible confounders. Experiment one– 1 hour immersion) To assess the effect of 1-h immersion on heart rate, frogs from three separate tanks were transferred to a holding bin and then chosen at random for 1 of 3 euthanasia solutions (30 frogs total; n = 10/group): 1) TMS-5 (5g/L MS-222, Syndel, Ferndale, WA); 2) TMS-10 (10 g/L MS-222); or 3) Bupi-1.5 (1.5 g/L bupivacaine, Hospira Inc., Lake Forest, IL). At the end of 1-h immersion, animals were removed from the euthanasia solutions, rinsed with fresh source water, replaced into a rinsed & emptied container, and kept moist with moistened paper towels. Heart rates (bpm) were evaluated audibly via doppler ultrasound flow at 1 h (T1h, the end of 1 h immersion), 2 (T2h), and 3 (T3h) h. Time for this assessment ranged from 20–30 min. At the end of the experiment, the animals were placed in dorsal recumbency for the last heart rate assessment. The withdrawal reflex was re-assessed & a celiotomy was then performed to visualize the heart; the animals were then euthanized via cardiectomy (Fig 1A). No animals were excluded from experiment one. Experiment two– 5 and 19 hour immersion) To assess the effect of an extended immersion time on heart rate, frogs from two separate tanks were randomly assigned to 1 of 2 euthanasia solutions (14 frogs total; n = 7/group): 1) TMS-5 (5g/L MS-222) or 2) Bupi-1.5 (1.5 g/L bupivacaine). Frogs were immersed in either of these solutions for 5 h (T5h). Frogs were removed from solutions at T5h to perform heart rate assessment with the same method as experiment 1. Time for this assessment ranged from 15–20 min. Frogs with heart beats still present after the T5h evaluation were replaced into their respective euthanasia solutions for a total immersion time of 19 h. A celiotomy was performed on frogs with ceased heart rates to confirm visual lack of heart beat and a cardiectomy was performed. Remaining frogs were removed from euthanasia solutions the next morning and evaluated visually for rigor mortis and for heart rate via celiotomy (Fig 1B).

Fig 1. Study design schematic.

Fig 1

A) 1-h immersion. B) 5-h & 19-h immersion. Dotted bar indicates length of time animals were immersed in solution. Heart rate assessment was performed via doppler ultrasound flow with the probe placed over the heart. Reflex assessment included withdrawal reflex of the right hindlimb and righting reflex. For A) a celiotomy was performed for all animals at the end of the experimental treatment. For B) a celiotomy was performed for frogs without audible heart beats using doppler ultrasound flow at 5-h of immersion & the remaining animals at 19-h of immersion.

Reflex assessment

Withdrawal reflex was performed once for both experiment one and two at 1 h and 2.5 h, respectively. To test withdrawal reflex to mechanical stimulus, the interdigital webbing of the right hindlimb was pinched once with mosquito hemostats. Righting reflex was performed each time heart rate assessment was performed for both experiments. To test righting reflex, frogs were turned to dorsal recumbency, if not already in this position, and observed for the ability to turn to ventral recumbency.

Results

1 hour immersion

There was no significant difference between any treatment group in heart rates after 1 h of immersion. The heart rate of animals immersed in Bupi-1.5 were significantly (P < 0.05) decreased compared to TMS-5 & TMS-10 g/L at 2h (10.8 ± 0.9, 17.4 ± 0.8, 17.4 ± 2.6 bpm, respectively). At 3 h post-immersion Bupi-1.5 was significantly decreased to only TMS-5 (8.2 ± 1.0 and 16.6 ± 1.1, respectively). There was no significant difference between the heart rates of animals in TMS-5 or TMS-10 at any time point (Fig 2).

Fig 2. Heart rate after 1-h immersion.

Fig 2

Heart rate (bpm; mean ± SEM) detected audibly via doppler ultrasound flow evaluation. * values are significantly different (P < 0.05) from each other. # values are significantly different (P < 0.05) between time points.

5 and 19 hour immersion

There was no significance difference between the TMS-5 and Bupi-1.5 groups at 5 h of immersion. At 5 h of immersion, we could not auscultate heart sounds in 3 of the TMS-5 treated frogs (43%) and 1 of the Bupi-1.5 treated frogs (14%); gross necropsy was performed, and the animals had zero visible cardiac contractions (Table 1). All animals with an audible heartbeat at 5 h were returned to their respective solutions and immersed for a total of 19 h. At 19 h, all remaining animals exhibited rigor mortis. Upon gross necropsy all cardiac activity was completely ceased (Fig 3 and Table 1).

Table 1. Animals with ceased heart rates after 5- & 19-h immersions.

T5h T19h
TMS-5 43% 100%
Bupi-1.5 14% 100%

Animals without audible or visual heart beats after 5-h and at 19-h (i.e. overnight) immersion are presented as percentages.

Fig 3. Heart rate after 5- & 19-h immersions.

Fig 3

Heart rate (bpm; mean ± SEM) detected audibly via doppler ultrasound evaluation. # values are significantly different (P < 0.05) between time points.

Statistical analysis

To assess significance of differences in heart rates (beats per minute) by group and over time, repeated-measures ANOVA with Bonferroni correction for multiple comparisons (R Development Core Team, 2015) was performed. Data were expressed as mean ± SEM. A P value of less than 0.05 was considered significant. To assess significance of differences between groups for number of animals with ceased heart rates after 5-h immersion a Fisher’s exact test was performed.

Discussion

This study demonstrates that: 1) 1-h immersion of African Clawed frogs in Bupi-1.5 has a faster onset to decrease heart rates compared to TMS-5 and TMS-10; 2) neither TMS-5, TMS-10, nor Bupi-1.5 resulted in complete cessation of heart rate after 1-h immersion; 3) at 19-h immersion, complete cessation of heart rate was observed in both TMS-5 and Bupi-1.5.

In the laboratory setting, groups of African Clawed frogs may need to be culled from colonies for health or experimental reasons. The euthanasia method should be reliable and relatively simple to perform. For individual animals, topical or injectable euthanasia methods are described, but may be logistically challenging and time consuming if larger groups must be culled [17]. In fish and amphibians, TMS acts centrally on the central nervous system to produce general anesthesia when the body is immersed in solution, and has also been investigated & utilized off-label for euthanasia [5, 6, 1824]. As discussed in the introduction, there are logistical drawbacks to utilizing TMS for this cause, prompting investigation for an alternative. In mammals, an overdose of bupivacaine is known to be toxic to the cardiovascular system compared to other local anesthetics due to increased lipophilicity, longer duration of blocking sodium channels, and high affinity for cardiac specific sodium channels [2527]. In dogs, a bupivacaine overdose causes significant hypotension and bradycardia including ventricular arrythmias contributing to cardiovascular collapse and death [28]. We hypothesized we could utilize these effects of bupivacaine overdose for African Clawed frogs. The aim of this study was to determine whether immersion in Bupi-1.5 (i.e. Bupivacaine at 1.5 g/L) would have a similar effect on heart rate as TMS-5 during the euthanasia process in African Clawed frogs.

1-hour immersion

For euthanasia of African Clawed frogs it is recommended to immerse animals in TMS-5 for minimum of 1 h, therefore heart rate was assessed immediately after 1 h, then at 2 and 3 h post the 1-h immersion for part one of the experiment. TMS-5, TMS-10, and Bupi-1.5 were utilized. TMS-10 was included as during a pilot study TMS-5 was observed to be insufficient in ceasing heart rate for immersed frogs, thus we expected twice the recommended concentration would be sufficient to achieve this endpoint. The AVMA euthanasia guidelines use irreversibility of death as part of the criteria for evaluating effective euthanasia methods [3]. For our study, we defined death as a total cessation of heart rate (i.e. cardiac death). We utilized an ultrasonic doppler flow detector to audibly evaluate heart rate for all frogs and visually observed heart movement at the end of each experiment and to confirm ceased heart rate.

Surprisingly, the heart rate of TMS-5 and TMS-10 frogs did not differ at any time point (Fig 2). A previous euthanasia study utilizing African Clawed frogs showed complete cessation of cardiac activity for all frogs at 3 h post a 1-h immersion in a TMS-5 solution [5]. However, in this current study, heart rates did not show complete cessation at 3 h post the 1-h immersion in either TMS-5 or TMS-10 groups (heart rates were 16.6 and 14.7 bpm, respectively). Although the definitive reason for this disparity between this current study and the 2009 study is unclear, the differences in age of the frogs may have contributed to the difference in outcome. Concentration and duration of TMS to effectively euthanize African Clawed frogs has also been shown to vary by life stage [23]. Whereas all frogs utilized in the 2009 study were aged 2–3 years old, we included retired breeders from various colonies whose age was not specified. Expected breeding years for female African Clawed frogs can range from 3–6 years, but frogs have been kept in laboratories for egg production for 12 years or more; it is very likely a number of our frogs exceeded 3 years of age [2].

In this current study, although it did not cease heart rate, Bupi-1.5 treated animals had lower heart rates compared to TMS-5 at 2 and 3 h post 1-h immersion, and lower heart rates compared to TMS-10 at 2 h (Fig 2). Bupivacaine is 2–4 times more cardiovascular toxic than other local anesthetics in mammals (e.g. lidocaine), hence it was selected for this current study, however a cardiovascular toxic dose for African Clawed frogs has not been established [28]. The concentration of bupivacaine in this experiment was selected based on data from a pilot study we conducted in which frogs were immersed in several concentrations of a bupivacaine solution and heart rate was assessed. In this current study the decreased heart rate of Bupi-1.5 animals compared to the TMS-5 and TMS-10 groups at any time point was likely due to overdose of bupivacaine. At 3 h post the 1-h immersion, none of the groups showed complete cessation of heart rate. The lack of cardiac death after the 1-h immersion at any time point in TMS-5, TMS-10, and Bupi-1.5 solutions for this study is strong support for the use of a secondary physical method of euthanasia after 1-h immersion. It should also be noted while bupivacaine does not pose the same potential eye hazard to humans as TMS, multiple vials had to be drawn up to create the 1.5 g/L solution, which should be factored in for time and labor.

5- and 19-hour immersion

Because complete cardiac cessation was not observed in the first experiment by 3 h post the 1-h immersion, we extended immersion time in this second experiment. This portion focused on TMS-5 as this dose is recommended within the AVMA Euthanasia guidelines and Bupi-1.5. Frogs were immersed for a longer duration at 5 or 19 h. A 5-h immersion represents a time scheme wherein animal care or laboratory personnel may begin a large group euthanasia at the start of a work day and complete the task before the end of the work day, while the 19-h immersion represents an overnight immersion. Heart rates were assessed utilizing the same method as experiment one immediately at each time point. Although the 5-h immersion showed no statistical difference in heart rate between TMS-5 or Bupi-1.5, a number of the frogs had ceased heart rate (i.e. absent cardiac sounds, no visual cardiac contractions after celiotomy) in both the TMS-5 and Bupi-1.5 groups (43% and 14%, respectively; Fig 3 and Table 1). It is possible that at the 5-h immersion, although heart rate was not completely ceased, the remaining frogs were on the pathway to brain death or irreversible cardiac collapse. In mammals, cardiac arrest without intervention has been shown to result in loss of brain activity within 30 seconds due to the high glucose and oxygen requirements of neural tissue [29]. However, in aquatic animals and reptiles cardiac activity can persist after brain death due to the myocardium utilizing local glycogen stores, as opposed to blood glucose [4, 8]. Anecdotally, this mechanism can even be observed with the heart removed from the body. However, to technically identify brain death, an electroencephalogram (EEG) must be performed, which is not an accessible tool for animal care personnel. Although EEG has been used to assess plane of anesthesia in TMS anesthetized African Clawed frogs, it was not utilized in this study [30].

After the 5 h heart rate assessment, the immersion time was continued until 19 h. At 19-h immersion, heart rate was not detected in any animals in either TMS-5 or Bupi-1.5 groups. All remaining frogs exhibited rigor mortis and had absent visible cardiac contractions upon celiotomy. As discussed, determining death using heart contractions in amphibians can be difficult due to the ability for persistent heart contractions after apparent euthanasia, however rigor mortis is a confirmatory sign of death [3]. Additionally, while African Clawed frogs live as aquatic amphibians, they are surface breathers [31]. It is likely some of the frogs died from lack of oxygen as they were under deep general anesthesia and could not surface for air [32]. Because the 19-h immersion represents an overnight euthanasia with the endpoint being death we did not assess heart rate between 5 and 19 h. Although the intention for using TMS and bupivacaine during the 19-h immersion was for the drugs to cause cessation of heart rate, if the animals succumb to lack of oxygen during this time instead, a humane death is still achieved. Both TMS-5 and Bupi-1.5 animals rapidly lost consciousness as indicated by absence of movement soon after immersion and loss of righting reflex, and remain anesthetized until they succumbed to death either from complete cessation of heart rate, and thus collapse of cardiac function, or lack of oxygen. Use of EEG, echocardiogram, and/or cardiac output measurements would aid in identifying if brain death occurs before cardiac death using this euthanasia technique. As drug dosage and efficacy has been demonstrated to differ between sexes in a number of species future studies should also include a male cohort to assess impact of sex on time to cease heart rate [3335].

In summary, this study indicates that 1) after a 1-h immersion, frogs in Bupi-1.5 had a faster initial onset to decreased heart rates compared to TMS-5 or TMS-10, however no solution ceased heart rate of any animal; 2) at 5-h immersion, 47% of TMS-5 & 17% of Bupi-1.5 treated animals had completely ceased heart rates 3) at 19-h immersion, heart rate of all frogs was completely ceased and all animals exhibited rigor mortis. The inconsistency in producing cardiac death throughout this study with any solution is strong support for the use of a secondary physical method of euthanasia when utilizing an immersive euthanasia method in African Clawed frogs.

Supporting information

S1 Table. Data used for Fig 2.

(TIF)

S2 Table. Data used for Fig 3.

(TIF)

Acknowledgments

We would like to thank Andrea Craig and Alberto Gaudiel for their assistance in care for the animals.

Data Availability

All data has been included within the paper text and its Supporting Information files.

Funding Statement

This work was supported by Stanford's Department of Comparative Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Stanford Department of Comparative Medicine or any other agency of the State of California.

References

  • 1.Hickman DL, Johnson J, Vemulapalli TH, Crisler JR, Shepherd R. Commonly Used Animal Models. 2016. In: Principles of Animal Research for Graduate and Undergraduate Students [Internet]. Elsevier; [117–64]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150119/. [Google Scholar]
  • 2.Green S. The Laboratory XENOPUS sp. Suckow M, editor. Boca Raton, FL: CRC Press; 2010. [Google Scholar]
  • 3.Guidelines for the Euthanasia of Animals2020 7-Sept-2022. Available from: https://www.avma.org/resources-tools/avma-policies/avma-guidelines-euthanasia-animals.
  • 4.Nevarez J. Euthanasia. In: Divers S, Stahl S, editors. Mader’s Reptile and Amphibian Medicine and Surgery. St. Louis, MO: Elsevier: Saunders; 2019. p. 437-40.e1. [Google Scholar]
  • 5.Torreilles SL, McClure DE, Green SL. Evaluation and refinement of euthanasia methods for Xenopus laevis. J Am Assoc Lab Anim Sci. 2009;48(5):512–6. [PMC free article] [PubMed] [Google Scholar]
  • 6.Chatigny F, Kamunde C, Creighton CM, Stevens ED. Uses and Doses of Local Anesthetics in Fish, Amphibians, and Reptiles. J Am Assoc Lab Anim Sci. 2017;56(3):244–53. [PMC free article] [PubMed] [Google Scholar]
  • 7.Pasmans F, Martel A. Amphibian Taxonomy, Anatomy, and Physiology. In: Divers S, Stahl S, editors. Mader’s Reptile and Amphibian Medicine and Surgery (Third Edition). 3 ed. St. Louis, MO: Elsevier; 2019. p. 86-9.e1. [Google Scholar]
  • 8.Stetter MD. Fish and amphibian anesthesia. Vet Clin North Am Exot Anim Pract. 2001;4(1):69–82, vii. doi: 10.1016/s1094-9194(17)30052-x [DOI] [PubMed] [Google Scholar]
  • 9.Collymore C. Anesthesia, Analgesia, and Euthanasia of the Laboratory Zebrafish. In: Cartner S, Eisen J, Farmer S, Guillemin K, Kent M, Sanders G, editors. The Zebrafish in Biomedical Research. American College of Laboratory Animal Medicine: Academic Press; 2020. p. 403–13. [Google Scholar]
  • 10.Neiffer DL, Stamper MA. Fish sedation, analgesia, anesthesia, and euthanasia: considerations, methods, and types of drugs. Ilar j. 2009;50(4):343–60. doi: 10.1093/ilar.50.4.343 [DOI] [PubMed] [Google Scholar]
  • 11.Readman GD, Owen SF, Knowles TG, Murrell JC. Species specific anaesthetics for fish anaesthesia and euthanasia. Sci Rep. 2017;7(1):7102. doi: 10.1038/s41598-017-06917-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mitchell M. Anesthetic Considerations for Amphibians. J Exotic Pet Med. 2009;18(1):40–9. [Google Scholar]
  • 13.Berenstein P, Digre K, Creel D. Retinal toxicity associated with occupational exposure to the fish anesthetic MS-222. Am J Ophthalmol. 1997;124(6):843–4. doi: 10.1016/s0002-9394(14)71705-2 [DOI] [PubMed] [Google Scholar]
  • 14.Katz EM, Chu DK, Casey KM, Jampachaisri K, Felt SA, Pacharinsak C. The Stability and Efficacy of Tricaine Methanesulfonate (MS222) Solution After Long-Term Storage. J Am Assoc Lab Anim Sci. 2020;59(4):393–400. doi: 10.30802/AALAS-JAALAS-19-000067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.de La Coussaye JE, Massé C, Bassoul BP, Eledjam JJ, Gagnol JP, Sassine A. Bupivacaine-induced slow-inward current inhibition: a voltage clamp study on frog atrial fibres. Can J Anaesth. 1990;37(7):819–22. doi: 10.1007/BF03006545 [DOI] [PubMed] [Google Scholar]
  • 16.Guerrero S, Morales M, Hernandez D. Electrophysiological effects of bupivacaine on transitional pacemaker cells of the frog heart. Arch Int Pharmacodyn Ther. 1987;288(1):59–70. [PubMed] [Google Scholar]
  • 17.Whitaker B, McDermott C. Amphibian Formulary. In: Divers S, Stahl S, editors. Mader’s Reptile and Amphibian Medicine and Surgery (Third Edition). 3 ed. St. Louis, MO: Elsevier; 2019. p. 1212–20.e2. [Google Scholar]
  • 18.Freedom of Information Summary: ANADA 200–226 Tricaine-S. US FDA.
  • 19.Balko J, Oda A, Posner L. Use of tricaine methanesulfonate or propofol for immersion euthanasia of goldfish (Carassius auratus). JAVMA. 2018;12(252):1555–61. doi: 10.2460/javma.252.12.1555 [DOI] [PubMed] [Google Scholar]
  • 20.Balko J, Posner L, Chinnadurai S. Immersion in Tricaine Methanesulfonate (MS-222) is not Sufficient for Euthanasia of Smokey Jungle Frogs (Leoptodactylus pentadactylus). J Zoo & Wildlife Med. 2019;50(1):89–95. [DOI] [PubMed] [Google Scholar]
  • 21.Collymore C, Tolwani A, Lieggi C, Rasmussen S. Efficacy and safety of 5 anesthetics in adult zebrafish (Danio rerio). J Am Assoc Lab Anim Sci. 2014;53(2):198–203. [PMC free article] [PubMed] [Google Scholar]
  • 22.Conroy CJ, Papenfuss T, Parker J, Hahn NE. Use of tricaine methanesulfonate (MS222) for euthanasia of reptiles. J Am Assoc Lab Anim Sci. 2009;48(1):28–32. [PMC free article] [PubMed] [Google Scholar]
  • 23.Galex IA, Gallant CM, D’Avignon N, Kuchenbrod LM, Fletcher CA, Rogala AR. Evaluation of Effective and Practical Euthanasia Methods for Larval African Clawed Frogs (Xenopus laevis). J Am Assoc Lab Anim Sci. 2020;59(3):269–74. doi: 10.30802/AALAS-JAALAS-19-000141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Butler-Struben HM, Brophy SM, Johnson NA, Crook RJ. In Vivo Recording of Neural and Behavioral Correlates of Anesthesia Induction, Reversal, and Euthanasia in Cephalopod Molluscs. Front Physiol. 2018;9:109. doi: 10.3389/fphys.2018.00109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Grubb T, Lobprise H. Local and regional anaethesia in dogs and cats: Overview of concepts and drugs (Part 1). Vet Med Sci. 2020;6(2):209–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Greensmith JE, Murray WB. Complications of regional anesthesia. Current Opinion in Anesthesiology. 2006;19(5):531–7. doi: 10.1097/01.aco.0000245280.99786.a3 [DOI] [PubMed] [Google Scholar]
  • 27.Butterworth JFt Strichartz GR. Molecular mechanisms of local anesthesia: a review. Anesthesiology. 1990;72(4):711–34. doi: 10.1097/00000542-199004000-00022 [DOI] [PubMed] [Google Scholar]
  • 28.Thomas RD, Behbehani MM, Coyle DE, Denson DD. Cardiovascular toxicity of local anesthetics: an alternative hypothesis. Anesth Analg. 1986;65(5):444–50. [PubMed] [Google Scholar]
  • 29.Pana R, Hornby L, Shemie SD, Dhanani S, Teitelbaum J. Time to loss of brain function and activity during circulatory arrest. Journal of Critical Care. 2016;34:77–83. doi: 10.1016/j.jcrc.2016.04.001 [DOI] [PubMed] [Google Scholar]
  • 30.Lalonde-Robert V, Desgent S, Duss S, Vachon P. Electroencephalographic and physiologic changes after tricaine methanesulfonate immersion of African clawed frogs (Xenopus laevis). J Am Assoc Lab Anim Sci. 2012;51(5):622–7. [PMC free article] [PubMed] [Google Scholar]
  • 31.Boutilier RG. Characterization of the intermittent breathing pattern in Xenopus laevis. Journal of Experimental Biology. 1984;110(1):291–309. doi: 10.1242/jeb.110.1.291 [DOI] [PubMed] [Google Scholar]
  • 32.Reed BT. Guidance for the housing and care of the African clawed frog, Xenopus laevis: RSPCA; 2005. Available from: https://www.med.hku.hk/Research/Ethics-and-Integrity/-/media/7E76B5A14CC74255BAA1FC4D9F1EBF15.ashx.
  • 33.Greenspan JD, Craft RM, LeResche L, Arendt-Nielsen L, Berkley KJ, Fillingim RB, et al. Studying sex and gender differences in pain and analgesia: a consensus report. Pain. 2007;132 Suppl 1:S26–45. doi: 10.1016/j.pain.2007.10.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Czerniak R. Gender-based differences in pharmacokinetics in laboratory animal models. Int J Toxicol. 2001;20(3):161–3. doi: 10.1080/109158101317097746 [DOI] [PubMed] [Google Scholar]
  • 35.Smith JC. A Review of Strain and Sex Differences in Response to Pain and Analgesia in Mice. Comp Med. 2019;69(6):490–500. doi: 10.30802/AALAS-CM-19-000066 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Rishabh Charan Choudhary

1 Sep 2022

PONE-D-22-17202Bupivacaine as a euthanasia agent for African Clawed Frogs (Xenopus laevis)PLOS ONE

Dear Dr. Navarro,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 16 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Rishabh Charan Choudhary

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

3. As part of your revision, please complete and submit a copy of the Full ARRIVE 2.0 Guidelines checklist, a document that aims to improve experimental reporting and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility: https://arriveguidelines.org/sites/arrive/files/Author%20Checklist%20-%20Full.pdf (PDF). Please include your completed checklist as a Supporting Information file. Note that if your paper is accepted for publication, this checklist will be published as part of your article.

4. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

5. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

   "We would like to thank Andrea Craig and Alberto Gaudiel for their assistance in care for the animals. The study was supported by the Stanford Department of Comparative Medicine."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

 "This work was supported by Stanford's Department of Comparative Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Stanford Department of Comparative Medicine or any other agency of the State of California."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

7. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Author,

This is an interesting. However ,lease elaborate the practical utility and implication of the present and advantage over other existing models.

How these dat can be used to expand knowledge in clinical or basic research files

Reviewer #2: The author is willing to share raw data upon request, however states that restrictions will apply as far as posting to a public repository. It is not included with the manuscript.

Manuscript review PONE-D-22-17202, entitled "Bupivacaine as a euthanasia agent for African Clawed Frogs (Xenopus laevis)".

Overall Comments: This manuscript describes the immersion of African Clawed frogs in bupivacaine or TMS for humane euthanasia. This information is beneficial to the research community and describes a potential novel euthanasia agent for this species, in that bupivacaine successfully lowered the heart rate more quickly than the standard immersion agent and produced irreversible death. This give the community another, safer, agent to use. It also shows the importance of using a secondary method of euthanasia when following the AVMA Guidelines for the use of TMS in this species. The study is described well and conclusion are appropriate.

Abstract, Line 31- 9 hours is stated, this should be 19.

Introduction, Line 47- Please add the word “and” between endocrinology and toxicology.

Materials and Methods, Line 110- Please add a sentence prior to “A celiotomy was performed…” on how it was confirmed a surgical plane of anesthesia was attained.

Results, Line 139- Please add a reference to Figure 2.

Discussion, Line 228-9- “brain death or irreversible” Please complete this sentence.

Figure 1B. There should be an indication that frogs without a heart beat had a celiotomy performed at the 5h timepoint.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Amit Agrawal

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Dec 21;17(12):e0279331. doi: 10.1371/journal.pone.0279331.r002

Author response to Decision Letter 0


10 Sep 2022

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: This has been revised.

2. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

Response: Thank you for the comment; this was included in our manuscript and can be located in the revised version in lines 104-108. The additional requirements of anesthesia and euthanasia can be found within the methods section.

3. As part of your revision, please complete and submit a copy of the Full ARRIVE 2.0 Guidelines checklist, a document that aims to improve experimental reporting and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility: https://arriveguidelines.org/sites/arrive/files/Author%20Checklist%20-%20Full.pdf (PDF). Please include your completed checklist as a Supporting Information file. Note that if your paper is accepted for publication, this checklist will be published as part of your article.

Response: This checklist has been completed and uploaded as a supplemental file.

4. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Response: This has been clarified in the resubmission process.

5. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"We would like to thank Andrea Craig and Alberto Gaudiel for their assistance in care for the animals. The study was supported by the Stanford Department of Comparative Medicine."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"This work was supported by Stanford's Department of Comparative Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Stanford Department of Comparative Medicine or any other agency of the State of California."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: Thank you. The funding statement in the manuscript has been removed. We have addressed the statement in our cover letter.

6. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Response: We have uploaded supplementary files to provide a minimal data set. All other data are included within the manuscript.

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

Response: We have uploaded supplementary files to provide a minimal data set. All other necessary data are included within the manuscript.

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Author, This is interesting. However, please elaborate the practical utility and implication of the present and advantage over other existing models.

How these data can be used to expand knowledge in clinical or basic research files.

Response: Thank you for your comment. We have added additional information elaborating on the importance of Xenopus as an animal research model, why large group culls may be necessary, and the importance of alternative euthanasia agents in the introduction.

Reviewer #2: The author is willing to share raw data upon request, however states that restrictions will apply as far as posting to a public repository. It is not included with the manuscript.

Response: We have uploaded supplementary files to provide a minimal data set. All other necessary data are included within the manuscript.

Reviewer 2: Abstract, Line 31- 9 hours is stated, this should be 19.

Response: Thank you, this has been revised.

Reviewer 2: Introduction, Line 47- Please add the word “and” between endocrinology and toxicology.

Response: Thank you, this has been revised.

Reviewer 2: Materials and Methods, Line 110- Please add a sentence prior to “A celiotomy was performed…” on how it was confirmed a surgical plane of anesthesia was attained.

Response: This has been revised to confirm a surgical plane of anesthesia had been attained prior to celiotomy and how it was performed.

Reviewer 2: Results, Line 139- Please add a reference to Figure 2.

Response: This has been added.

Reviewer 2: Discussion, Line 228-9- “brain death or irreversible” Please complete this sentence.

Response: Thank you, this has been revised.

Reviewer 2: Figure 1B. There should be an indication that frogs without a heart beat had a celiotomy performed at the 5h timepoint.

Response: The figure has been updated to reflect the celiotomy at 5h and the figure text has been updated to reflect when celiotomies were performed and for which animals.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Michael Klymkowsky

5 Dec 2022

Bupivacaine as a euthanasia agent for African Clawed Frogs (Xenopus laevis)

PONE-D-22-17202R1

Dear Dr. Navarro,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hazel Bautista

Support Staff - Lead

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have made suggested changes

The practical of study has been added

The data sets have been made available

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Amanda Darbyshire

**********

Acceptance letter

Michael Klymkowsky

12 Dec 2022

PONE-D-22-17202R1

Bupivacaine as a euthanasia agent for African Clawed Frogs (Xenopus laevis)

Dear Dr. Navarro:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michael Klymkowsky

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Data used for Fig 2.

    (TIF)

    S2 Table. Data used for Fig 3.

    (TIF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All data has been included within the paper text and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES